Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Observational

FARD (RaDiCo Cohort) (RaDiCo-FARD)

NCT05954416 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2018-03-07
Last updated
2026-02-12

Condition(s) studied

Inherited Epidermolysis BullosaIchthyosisEctodermal DysplasiaIncontinentia PigmentiNeurofibromatosis Type 1AlbinismPemphigusMucous Membrane PemphigoidPalmoplantar Keratoderma

Study summary

The goal of this observational study is to conduct a prospective assessment of the individual Burden of 9 rare skin diseases to assess disability in the broadest sense of the term (psychological, social, economic and physical) for patients and/or families.

Two types of indicators will be used to reach this objective :

1. an individual burden score calculated based on a burden questionnaire created specifically, approved and designed to understand the tendency to changes in care and lifestyles. The burden questionnaire should be used by patients and/or their family themselves in self-assessment.
2. a descriptive analysis of all resources (medical and non-medical) used by the family unit to manage the disease.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion criteria : * adults or children with a confirmed diagnosis of one of the 9 following rare skin disease: Inherited epidermolysis bullosa, Ichthyosis, Ectodermal dysplasia, Incontinetia Pigmenti, Neurofibromatosis type 1, Albinism, Pemphigus, Mucous membrane pemphigoid or Palmoplantar keratoderma. * prevalent or incident and followed in one the reference/competence centers of the FIMARAD healthcare network, * able to understand a survey (for child, survey should be understood by parents), * having given their signed consent to participate to the cohort RaDiCo-FARD (parents' consent for child). Non-inclusion criteria : * Patients, for whom regular care follow-up is not feasible with the FIMARAD healthcare network sites, * Unconfirmed diagnosis (according to criteria for each disease), * Patients (and/or parents) not able to understand a survey * Patients (and/or parents) not having given their signed consent to participate to the study

Primary outcome measure(s)

  • Individual burden score for each selected rare disease — Through study completion, an average of 5 years
    Before 16 years old, we will focus on the burden of families. After 16 years old, the patient's parent will continue to answer to the family Burden questionnaire and the patient will start to answer to the adult's Burden questionnaire.

Trial sites (15)

FacilityCityRegionStatus
Hôpital Avicenne Bobigny France Not Yet Recruiting
Hôpital des Enfants - Groupe Hospitalier Pellegrin Bordeaux France Not Yet Recruiting
Hôpital des Enfants - Groupe Hospitalier Pellegrin Bordeaux France Not Yet Recruiting
Hôpital Henri-Mondor Créteil France Not Yet Recruiting
Hôpital François Mitterrand Dijon France Not Yet Recruiting
Hôpital Dupuytren Limoges France Not Yet Recruiting
Hôpital de la Timone Marseille France Not Yet Recruiting
Hôpital Saint-Eloi Montpellier France Not Yet Recruiting
Hôpital l'Archet Nice France Recruiting
Hôpital Necker-Enfants Malades Paris France Recruiting
Hôpital Saint-Louis Paris France Recruiting
Hôpital Robert-Debré Reims France Not Yet Recruiting
Hôpital Charles Nicolle Rouen France Recruiting
Hôpital Larrey Toulouse France Recruiting
Hôpital Trousseau Tours France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05954416 on ClinicalTrials.gov ↗ ← All trials in France